Guangzhou Baiyunshan Pharmaceutical Holdings Company's market cap is currently ―. The company's EPS TTM is $0.352; its P/E ratio is 8.36; and it has a dividend yield of 3.53%. Guangzhou Baiyunshan Pharmaceutical Holdings Company is scheduled to report earnings on August 16, 2024, and the estimated EPS forecast is $0.07. See an overview of income statement, balance sheet, and cash flow financials.

	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21
Income Statement	-
Total Revenue	¥ 15.98B	¥ 17.59B	¥ 16.68B	¥ 20.54B	¥ 15.47B
Gross Profit	¥ 2.44B	¥ 3.13B	¥ 2.87B	¥ 4.84B	¥ 2.40B
EBIT	¥ 710.41M	¥ 1.23B	¥ 1.17B	¥ 2.37B	¥ 626.65M
EBITDA	¥ 710.41M	¥ 1.23B	¥ 1.17B	¥ 2.37B	¥ 626.65M
Net Income Common Stockholders	¥ 492.16M	¥ 884.37M	¥ 784.36M	¥ 1.81B	¥ 408.14M
Balance Sheet	-
Cash, Cash Equivalents and Short-Term Investments	¥ 22.56B	¥ 21.72B	¥ 22.60B	¥ 23.58B	¥ 22.38B
Total Assets	¥ 74.67B	¥ 69.55B	¥ 66.80B	¥ 67.04B	¥ 66.12B
Total Debt	¥ 11.43B	¥ 11.30B	¥ 10.90B	¥ 11.17B	¥ 9.92B
Net Debt	¥ -11.13B	¥ -10.43B	¥ -11.70B	¥ -12.41B	¥ -12.45B
Total Liabilities	¥ 41.03B	¥ 35.67B	¥ 33.84B	¥ 33.83B	¥ 34.79B
Stockholders Equity	¥ 32.07B	¥ 31.43B	¥ 30.54B	¥ 30.87B	¥ 29.06B
Cash Flow	-
Free Cash Flow	¥ 3.21B	¥ 1.24B	¥ 518.21M	¥ 643.42M	¥ -596.62M
Operating Cash Flow	-	-	-	-	-
Investing Cash Flow	¥ -1.38B	¥ -3.24B	¥ -2.20B	¥ -429.20M	¥ -371.25M
Financing Cash Flow	¥ -1.25B	¥ 196.77M	¥ 245.87M	¥ 848.64M	¥ -1.27B

Currency in CNY

Guangzhou Baiyunshan Pharmaceutical Holdings Company Earnings and Revenue History

Income Statement >

Guangzhou Baiyunshan Pharmaceutical Holdings Company Debt to Assets

Balance Sheet >

Guangzhou Baiyunshan Pharmaceutical Holdings Company Cash Flow

Cash Flow >

Guangzhou Baiyunshan Pharmaceutical Holdings Company Forecast EPS vs Actual EPS

Earnings >

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing